


# Autolus

NASDAQ: AUTL



## Financial Results and Operational Highlights for Transition Period October 1 – December 31, 2018

February 25, 2019

# Disclaimers

These slides and the accompanying oral presentation contain forward-looking statements, including statements about the Company's plans to develop and commercialize its product candidates, the Company's ongoing and planned clinical trials, the anticipated benefits of the Company's product candidates, the timing and availability of data from clinical trials, the timing and ability to obtain and maintain regulatory approvals for the Company's product candidates and the size and growth potential of the markets for its product candidates. All statements other than statements of historical fact contained in this presentation, including statements regarding the Company's future results of operations and financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar expressions. These statements involve known and unknown risks, uncertainties and other important factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed on November 23, 2018 as well as discussions of potential risks, uncertainties, and other important factors in Autolus' future filings with the Securities and Exchange Commission from time to time. All information in this presentation is as of the date hereof, and the company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.

Certain data in this presentation was obtained from various external sources. Such data speak only as of the date referenced in this presentation and neither the Company nor its affiliates, advisors or representatives make any representation as to the accuracy or completeness of that data or undertake to update such data after the date of this presentation. Such data involve risks and uncertainties and are subject to change based on various factors.

# Agenda for today

1. Corporate Overview and Introduction: Dr. Christian Itin, Chairman and CEO
2. Operational Highlights: Dr. Christian Itin
3. Financial Results and Overview: Andrew J. Oakley, Chief Financial Officer
4. Upcoming Milestones and Conclusion: Dr. Christian Itin
5. Q&A: Dr. Christian Itin; Andrew Oakley; and Christopher Vann, Chief Operating Officer

# Operational Highlights

*Dr. Christian Itin*  
*Chairman and CEO*

# Autolus pipeline

Product	Indication	Target	Preclinical	Phase 1/2	Phase 2/3
<b>B Cell Malignancies</b>					
AUTO1	Pediatric ALL	CD19	UCL - CARPALL		
AUTO1	Adult ALL	CD19	UCL - ALLCAR19		
AUTO3	Pediatric ALL	CD19 & CD22	AMELIA		
AUTO3	DLBCL	CD19 & CD22	ALEXANDER		
AUTO3 NG	B-Cell Malignancies	Undisclosed			
<b>Multiple Myeloma</b>					
AUTO2	Multiple Myeloma	BCMA & TACI			
AUTO2 NG	Multiple Myeloma	Undisclosed			
<b>T Cell Lymphoma</b>					
AUTO4	TRBC1+ Peripheral TCL (LibRA-T1)	TRBC1	LibrA-T1		
AUTO5	TRBC2+ Peripheral TCL	TRBC2			
<b>GD2+ Tumors</b>					
AUTO6	Neuroblastoma	GD2	CRUK		
AUTO6 NG	Neuroblastoma; Melanoma; Osteosarcoma; SCLC	Undisclosed			
<b>Prostate Cancer</b>					
AUTO7	Prostate Cancer	Undisclosed			

NG = Next Generation  
SCLC = Small Cell Lung Cancer

# Additional company highlights

- Progress in building new manufacturing capabilities
  - CATAPULT facility operational in Stevenage, UK
  - Lease signed for global viral vector supply and launch facility in Enfield, U.K. (GRiD)
  - Lease signed for build to suit manufacturing center and U.S. HQ in Rockville, MD
  - New systems to efficiently manage all aspects of large-scale manufacture and certification of supply
- Build-out of management team

# Financial Results

*Andrew J. Oakley*  
*Chief Financial Officer*

# Transition period for 4Q 2018

## Well positioned for growth

USD m	4Q18	4Q17*	Variance
Grant Income	0.3	0.2	0.1
R&D	17.7	5.6	12.0
G&A	7.6	3.1	4.6
<b>Operating Loss</b>	<b>(25.0)</b>	<b>(8.4)</b>	<b>(16.6)</b>
Other Income	1.8	(0.5)	2.3
Tax Benefit	2.6	1.4	0.9
<b>Net Loss</b>	<b>(20.6)</b>	<b>(7.5)</b>	<b>(13.4)</b>
<b>Cash Balance</b>	<b>217.5</b>	<b>129.0</b>	<b>88.5</b>

\* Unaudited

# Upcoming Milestones and Conclusion

*Dr. Christian Itin*  
*CEO and Chairman*

# Expected 2019 clinical newsflow

*Expect two programs to progress to registration trials; will provide updates on all programs*

Program	Q4 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019
AUTO1 – Adult ALL		◆			◆
AUTO2 - MM					◆
AUTO3 - DLCBC	◆				◆
AUTO3 – Pediatric ALL	◆		◆		◆
AUTO4 – T-Cell Lymphoma			◆		◆
AUTO5 – T-Cell Lymphoma	◆				◆
Multiple Next Generation Programs					◆

◆ Pre-clinical    ◆ Phase 1 Initial data    ◆ Phase 1 full data

## **Q&A**

***Dr Christian Itin (CEO and Chairman)***

***Andrew Oakley (CFO)***

***Christopher Vann (COO)***

**Thank you.**

Autolus